Jeffrey Coleman is a senior associate in the Litigation/Controversy Department, who focuses his practice on intellectual property and patent litigation matters. Dr. Coleman conducted his doctoral research at The Pennsylvania State University, where his thesis focused on the prevention of pancreatic cancer cell proliferation by activation of the nuclear receptor PPAR-beta/delta.
Specifically, his research aimed to determine the roles of PPAR-beta/delta and the transcriptional repressor BCL-6 in mediating pancreatic cancer cell gene transcription, inflammation and invasion. Dr. Coleman was also a post-doctoral researcher at New York University School of Medicine.
Dr. Coleman has published papers in peer-reviewed scientific journals and has presented his research at annual meetings of the Society of Toxicology. Prior to joining the firm, Dr. Coleman was a biochemistry content consultant and test item writer for the American Institutes for Research. Dr. Coleman is a member of the New York State Bar Association.
JD, Fordham University School of Law, 2014
PhD, Molecular Toxicology, Pennsylvania State University, 2010